---
schema_version: "secwatch.filing_event.v1"
accession: "0000200406-23-000094"
form_type: "8-K"
ticker: "JNJ"
cik: "0000200406"
company_name: "JOHNSON & JOHNSON"
filed_at: "2023-10-17T23:59:59+00:00"
generated_at: "2026-06-09T22:53:00.799360+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# JNJ Q3 adjusted EPS $2.66 rises 19% YoY; $21.7B gain from Kenvue separation

## Summary
- Q3 sales $21.35B (+6.8% YoY); adjusted diluted EPS $2.66 (+19.3% YoY from $2.23).
- Innovative Medicine revenue $13.89B (+5.1% reported); MedTech $7.46B (+10.0%).
- U.S. sales grew 11.1% to $11.996B; international sales rose 1.6% to $9.355B.
- Discontinued ops net earnings $21.7B (incl. gain from Kenvue separation) vs $148M prior year.
- Adjusted pretax income from continuing ops $8.03B, up 13.8% YoY.

## SEC filing metadata
- accession: 0000200406-23-000094
- form_type: 8-K
- ticker: JNJ
- cik: 0000200406
- company_name: JOHNSON & JOHNSON
- filed_at: 2023-10-17T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/200406/000020040623000094/0000200406-23-000094-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/200406/000020040623000094/jnj-20231017.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000200406-23-000094
- JSON: https://secwatch.observer/filing/0000200406-23-000094.json
- Plain text: https://secwatch.observer/filing/0000200406-23-000094.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.